How to buy C4 Therapeutics stock (C4 Therapeutics)

C4 Therapeutics is a biotechnology business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.87 – an increase of 5.88% over the previous week. C4 Therapeutics employs 145 staff and has a trailing 12-month revenue of around $33.7 million.

Our top picks for where to buy C4 Therapeutics Inc stock

Buy C4 Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

C4 Therapeutics stock price (NASDAQ: CCCC)

Use our graph to track the performance of CCCC stocks over time.

C4 Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$3.87
52-week range	$3.61 - $11.88
50-day moving average more info button	$5.14
200-day moving average more info button	$6.07
Wall St. target price	$14.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.71

Is it a good time to buy C4 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

C4 Therapeutics price performance over time

Historical closes compared with the close of $3.87 from 2024-12-24

1 week (2024-12-19)	0.65%
1 month (2024-11-26)	-7.64%
3 months (2024-09-25)	-38.18%
6 months (2024-06-25)	-17.83%

1 year (2023-12-22)	-13.23%
2 years (2022-12-23)	-36.35%
3 years (2021-12-23)	33.38
5 years (2019-12-22)	N/A

C4 Therapeutics financials

Revenue TTM	$33.7 million
Gross profit TTM	$-86,745,000
Return on assets TTM	-20.61%
Return on equity TTM	-46%
Profit margin	0%
Book value	$3.44
Market Capitalization more info button	$258 million

TTM: trailing 12 months

C4 Therapeutics share dividends

We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

C4 Therapeutics share price volatility

Over the last 12 months, C4 Therapeutics's shares have ranged in value from as little as $3.61 up to $11.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while C4 Therapeutics's is 3.056. This would suggest that C4 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put C4 Therapeutics's beta into context you can compare it against those of similar companies.

• Regeneron Pharmaceuticals (REGN.US): 0.142
• Biogen (BIIB.US): -0.061
• Alector (ALEC.US): 0.657

C4 Therapeutics overview

C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. ; Biogen MA, Inc.

Frequently asked questions

null
What percentage of C4 Therapeutics is owned by insiders or institutions?
Currently 11.435% of C4 Therapeutics shares are held by insiders and 92.657% by institutions. How many people work for C4 Therapeutics?
Latest data suggests 145 work at C4 Therapeutics. When does the fiscal year end for C4 Therapeutics?
C4 Therapeutics's fiscal year ends in December. Where is C4 Therapeutics based?
C4 Therapeutics's address is: 490 Arsenal Way, Watertown, MA, United States, 02472 What is C4 Therapeutics's ISIN number?
C4 Therapeutics's international securities identification number is: US12529R1077